Lipid peroxidation and transforming growth factor-β1 levels in gastric cancer at pathologic stages

KEMİK SARBAY, Ahu; KEMİK, Özgür; TÜZÜN, Sefa; Pergel, Ahmet; Yücel, Ahmet Fikret

Lipid peroxidation and transforming growth factor-β1 levels in gastric cancer at pathologic stages

Sefa TÜZÜN, (SB Haseki Eğitim ve Araştırma Hastanesi, 2. Cerrahi Kliniği, İstanbul, Türkiye)

Ahmet Fikret YÜCEL, (Recep Tayyip Erdoğan Üniversitesi, Tıp Fakültesi, Cerrahi Anabilim Dalı, Rize, Türkiye)

Ahmet PERGEL, (Recep Tayyip Erdoğan Üniversitesi, Tıp Fakültesi, Cerrahi Anabilim Dalı, Rize, Türkiye)

Ahu KEMİK SARBAY, (İstanbul Üniversitesi, Cerrahpaşa Tıp Fakültesi, Biyokimya Anabilim Dalı, İstanbul, Türkiye)

Özgür KEMİK (Yüzüncü Yıl Üniversitesi, Tıp Fakültesi, Cerrahi Anabilim Dalı, Van, Türkiye)

Balkan Medical Journal

2 2

Yıl: 2012 Cilt: 29 Sayı: 3 Sayfa Aralığı: 273 - 276 Metin Dili: Türkçe İndeks Tarihi: 29-07-2022

Lipid peroxidation and transforming growth factor-β1 levels in gastric cancer at pathologic stages

Öz:

Amaç: Yüksek TGF-β1 seviyeleri ve gelişmiş TGF-β1 reseptör sinyalizasyonu mide kanseri patolojisi ile ilişkilidir. Bu etki oksidatif stres ve lipid peroksidasyon ürünleri tarafından oluşmaktadır. Bu çalışmada amaç, mide kanserli hastalarda TGF-β1 ve lipit peroksidasyon ürün düzeylerini ve bu ürünlerin patolojik evre ile korelasyonunu araştırmaktı. Materyal ve Metod: Mide kanserli 50 hasta ve sağlıklı 18 kişinin serumunda lipid peroksidasyon ürün ve TGF-β1 seviyelerine bakıldı. Sonuçlar: T2, T3 ve T4 tümörlü hastaların HNE ve TGF-β1 seviyeleri hem T1 hem de sağlıklı kişilere göre anlamlı derecede yüksek bulundu (p<0.001). TGF-β1 seviyeleri patolojik evre ile korele idi (r=0.702, p<0.05). Sonuç: Bu markırların üretimi, tümör anjiyogenezisine katkıda bulunabilir ve mide kanseri prognozunun belirlenmesinde yardımcı olabilir.

Anahtar Kelime:

Konular: Cerrahi

Öz:

Objective: High levels of TGF-β1 and enhanced TGF-β1 receptor signaling are related to the pathology of gastric cancer. This effect is caused by oxidative stress and lipid peroxidation products. The aim of this study was to investigate the levels of TGF-β1 and lipid peroxidation products in gastric cancer patients and their correlation with pathologic stage. Material and Methods: Lipid peroxidation products and TGF-β1 levels were studied in the serum samples of 50 gastric cancer patients and 18 control subjects. Results: HNE-protein adducts and TGF-β1 levels were significantly higher in T2, T3 and T4 gastric cancers than in either the T1 stage or controls (p<0.001). Pathologic stage was correlated with TGF-β1 levels (r=0.702, p<0.05). Conclusion: These markers production may contribute to tumor angiogenesis and aid in the prognosis of the gastric cancer.

Anahtar Kelime:

Konular: Cerrahi

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Akgül H, Ünal E, Demirci S, Kocaoğlu H, Bayar S. Mide Kanserinde D2-3 Diseksiyon Deneyimimiz. T Klin Cerrahi 1999;4:211-5.
2. Dicken BJ, Bigam DL, Cass C, Mackey JR, Joy AA, Hamilton SM. Gastric Adenocarcinoma: review and considerations for future directions. Ann Surg 2005;241:27-39.
3. Green D, Ponce de Leon S, Leon-Rodriguez E, Sosa-Sanchez R. Adenocarcinoma of the stomach: univariate and multivariate analysis of factors associated with survival. Am J Clin Oncol 2002;25:84-9. [CrossRef]
4. Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors 1993;8:1-9. [CrossRef]
5. Massagué J. TGF-beta signaling: receptors, transducers, and Mad proteins. Cell 1996;85:947-50. [CrossRef]
6. Geiser AG, Busam KJ, Kim SJ, Lafyatis R, O’Reilly MA, Webbink R, et al. Regulation of the transforming growth factor -beta1 and -beta3 promoters by transcription factor Sp1. Gene 1993;129:223-8. [CrossRef]
7. Grande JP. Role of the transforming growth factor-beta in tissue injury and repair. Proc Soc Exp Biol Med 1997;214:27-40.
8. Massagué J, Cheifetz S, Laiho M, Ralph DA, Weis FM, Zentella A. Transforming growth factor-beta. Cancer Surv 1992;12:81-103.
9. Winesett MP, Ramsey GW, Barnard JA. Type II TGF (beta) receptor expression in intestinal cell lines and in the intestinal tract. Carcinogenesis 1996;17:989-95. [CrossRef]
10. Landström M, Eklov S, Colosetti P, Nilsson S, Damber JE, Bergh A, et al. Estrogen induces apoptosis in a rat prostatic adenocarcinoma: association with an increased expression of TGF-beta 1 and its type-I and type-II receptors. Int J Cancer 1996;67:573-9. [CrossRef]
11. Sun L, Wu G, Willson JK, Zborowska E, Yang J, Rajkarunanayake I, et al. Expression of transforming growth factor beta type II receptor leads to reduced malignancy in human breast cancer MCF-7 cells. J Biol Chem 1994;269:26449-55.
12. Kim WS, Park C, Jung YS, Kim HS, Han J, Park CH, et al. Reduced transforming growth factor-beta type II receptor (TGFbeta RII) expression in adenocarcinoma of the lung. Anticancer Res 1999;19:301-6.
13. Leonarduzzi G, Scavazza A, Biasi F, Chiarpotto E, Camandola S, Vogel S, et al. The lipid peroxidation end product 4-hydroxy-2,3- nonenal up-regulates transforming growth factor beta1 expresssion in the macrophage lineage: a link between oxidative injury and fibrosclerosis. FASEB J 1997;11:851-7.
14. Dianzani MU. Lipid peroxidation and cancer. Crit Rev Oncol Hematol 1993;15:125-47. [CrossRef]
15. Ellis FH Jr, Heatley GJ, Balogh K. Proposal for improved staging criteria for carcinoma of the esophagus and cardia. Eur J Cardiothorac Surg 1997;12:361-4. [CrossRef]
16. Carini R, Mazzanti M, Biasi F. Fluorescent aldehyde-protein adducts in the blood serum of healthy alcoholics. Alcohol Toxicity and Free Radical Mechanisms Oxford: Pergamon Press, 1988; 664.
17. Tsuchida M, Miura T, Mizutani K, Aibara K. Fluorescence substances in mouse and human sera as a parameter of in vivo lipid peroxidation. Biochim Biophys Acta 1985;834:196-204. [CrossRef]
18. Esterbauer H, Cheeseman H. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol 1990;186:407-21. [CrossRef]
19. Wrana J, Attisano L, Wieser R, Ventura F, Massagué J. Mechanism of the activation of the TGF-beta receptor. Nature 1992;370:341-7. [CrossRef]
20. Moustakas A, Lin HY, Henis YI, Plamondon J, O’Connor-McCourt MD, Lodish HF. The TGF-beta receptors types I, II, and III form hetero-oligomeric complexes in the presence of ligand. J Biol Chem 1993;268:22215-8.
21. Wells RG, Gilboa L, Sun Y, Liu X, Henis YI, Lodish HF. Transforming growth factor-beta induces formation of a dithiothreitol-resistant typeI/Type II receptor complex in live cells. J Biol Chem 1999;274:5716-22. [CrossRef]
22. Chen RH, Ebner R, Drynck R. Inactivation of the type II receptor reveals two receptor pathways for the diverse TGF-beta activities. Science 1993;260:1335-8. [CrossRef]
23. Miettinen PJ, Ebner R, Lopez AR, Derynck R. TGF-beta induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors. L Cell Biol 1994;127:2021-36. [CrossRef]
24. Poli G, Parola M. Oxidative damage and fibrogenesis. Free Radic Biol Med 1997;22:287-305. [CrossRef]
25. Poli G. Pathogenesis of liver fibrosis: role of oxidative stress. Mol Aspects Med 2000;21:49-98. [CrossRef]
26. Parola M, Muraca R, Dianzoni I, Barrera G, Leonarduzzi G, Bendinelli P, et al. Vitamin E dietary supplementation inhibits transforming growth factor beta 1 gene expression in the rat liver. FEBS Lett 1992;308:267-70. [CrossRef]
27. Parola M, Pinzani M, Casini A, Albano E, Poli G, Gentilini A, et al. Stimulation of lipid peroxidation or 4-hydroxynonenal treatment increases procollagen alpha 1 (I) gene expression in human liver fat-storing cells. Biochem Biophys Res Commun 1993;194:1044-50. [CrossRef]
28. Pietrangelo A, Gualdi R, Casalgrandi G, G, Montosi G, Ventura E. Molecular and cellular aspects of iron-induced hepatic cirrhosis in rodents. J Clin Invest 1995;95:1824-31. [CrossRef]
29. Kuwahara A, Katano M, Nakamura M, Fujimoto K, Miyazaki K, Mori M, et al. New therapeutic strategy for gastric carcinoma: a two-step evaluation of malignant potential from its molecular biologic and pathologic characteristics. J Surg Oncol 1999;72:142-9. [CrossRef]
30. Szkaradkiewicz A, Karpiński TM, Drews M, Borejsza-Wysocki M, Majewski P, Andrzejewska E. Natural killer cell cytotoxicity and immunosuppressive cytokines (IL-10, TGF-beta1) in patients with gastric cancer. J Biomed Biotechnol 2010;2010:901564.
31. Jo Y, Han SU, Kim YJ, Kim JH, Kim ST, Kim SJ, et al. Suppressed Gastric Mucosal TGF-beta1 Increases Susceptibility to H. pylori- Induced Gastric Inflammation and Ulceration: A Stupid Host Defense Response. Gut Liver 2010;4:43-53. [CrossRef]
32. Hawinkels LJ, Verspaget HW, van Duijn W, van der Zon JM, Zuidwijk K, Kubben FJ, et al. Tissue level, activation and cellular localisation of TGF-beta1 and association with survival in gastric cancer patients. Br J Cancer 2007;97:398-404. [CrossRef]
33. Li X, Zhang YY, Wang Q, Fu SB. Association between endogenous gene expression and growth regulation induced by TGF-beta1 in human gastric cancer cells. World J Gastroenterol 2005;11:61-8.

APA	TÜZÜN S, Yücel A, Pergel A, KEMİK SARBAY A, KEMİK Ö (2012). Lipid peroxidation and transforming growth factor-β1 levels in gastric cancer at pathologic stages. , 273 - 276.
Chicago	TÜZÜN Sefa,Yücel Ahmet Fikret,Pergel Ahmet,KEMİK SARBAY Ahu,KEMİK Özgür Lipid peroxidation and transforming growth factor-β1 levels in gastric cancer at pathologic stages. (2012): 273 - 276.
MLA	TÜZÜN Sefa,Yücel Ahmet Fikret,Pergel Ahmet,KEMİK SARBAY Ahu,KEMİK Özgür Lipid peroxidation and transforming growth factor-β1 levels in gastric cancer at pathologic stages. , 2012, ss.273 - 276.
AMA	TÜZÜN S,Yücel A,Pergel A,KEMİK SARBAY A,KEMİK Ö Lipid peroxidation and transforming growth factor-β1 levels in gastric cancer at pathologic stages. . 2012; 273 - 276.
Vancouver	TÜZÜN S,Yücel A,Pergel A,KEMİK SARBAY A,KEMİK Ö Lipid peroxidation and transforming growth factor-β1 levels in gastric cancer at pathologic stages. . 2012; 273 - 276.
IEEE	TÜZÜN S,Yücel A,Pergel A,KEMİK SARBAY A,KEMİK Ö "Lipid peroxidation and transforming growth factor-β1 levels in gastric cancer at pathologic stages." , ss.273 - 276, 2012.
ISNAD	TÜZÜN, Sefa vd. "Lipid peroxidation and transforming growth factor-β1 levels in gastric cancer at pathologic stages". (2012), 273-276.

APA	TÜZÜN S, Yücel A, Pergel A, KEMİK SARBAY A, KEMİK Ö (2012). Lipid peroxidation and transforming growth factor-β1 levels in gastric cancer at pathologic stages. Balkan Medical Journal, 29(3), 273 - 276.
Chicago	TÜZÜN Sefa,Yücel Ahmet Fikret,Pergel Ahmet,KEMİK SARBAY Ahu,KEMİK Özgür Lipid peroxidation and transforming growth factor-β1 levels in gastric cancer at pathologic stages. Balkan Medical Journal 29, no.3 (2012): 273 - 276.
MLA	TÜZÜN Sefa,Yücel Ahmet Fikret,Pergel Ahmet,KEMİK SARBAY Ahu,KEMİK Özgür Lipid peroxidation and transforming growth factor-β1 levels in gastric cancer at pathologic stages. Balkan Medical Journal, vol.29, no.3, 2012, ss.273 - 276.
AMA	TÜZÜN S,Yücel A,Pergel A,KEMİK SARBAY A,KEMİK Ö Lipid peroxidation and transforming growth factor-β1 levels in gastric cancer at pathologic stages. Balkan Medical Journal. 2012; 29(3): 273 - 276.
Vancouver	TÜZÜN S,Yücel A,Pergel A,KEMİK SARBAY A,KEMİK Ö Lipid peroxidation and transforming growth factor-β1 levels in gastric cancer at pathologic stages. Balkan Medical Journal. 2012; 29(3): 273 - 276.
IEEE	TÜZÜN S,Yücel A,Pergel A,KEMİK SARBAY A,KEMİK Ö "Lipid peroxidation and transforming growth factor-β1 levels in gastric cancer at pathologic stages." Balkan Medical Journal, 29, ss.273 - 276, 2012.
ISNAD	TÜZÜN, Sefa vd. "Lipid peroxidation and transforming growth factor-β1 levels in gastric cancer at pathologic stages". Balkan Medical Journal 29/3 (2012), 273-276.